Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction.
<h4>Aim</h4>Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) with preserved left ventricular ejection fraction (LVEF), typically presenting as restrictive cardiomyopathy. The potential co-existence of ATTR-CA with systolic heart failur...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0254104&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850046381906984960 |
|---|---|
| author | Sorel Goland Igor Volodarsky Yacov Fabricant Shay Livschitz Sagi Tshori Valeri Cuciuc Liaz Zilberman Irena Fugenfirov Valeri Meledin Sara Shimoni Sagie Josfberg Jacob George |
| author_facet | Sorel Goland Igor Volodarsky Yacov Fabricant Shay Livschitz Sagi Tshori Valeri Cuciuc Liaz Zilberman Irena Fugenfirov Valeri Meledin Sara Shimoni Sagie Josfberg Jacob George |
| author_sort | Sorel Goland |
| collection | DOAJ |
| description | <h4>Aim</h4>Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) with preserved left ventricular ejection fraction (LVEF), typically presenting as restrictive cardiomyopathy. The potential co-existence of ATTR-CA with systolic heart failure has not been studied. The aim of this study is to describe the prevalence of ATTR-CA and its clinical characteristics in HF patients with reduced LVEF.<h4>Methods</h4>Patients with an unexplained cause of LV systolic dysfunction were screened for ATTR-CA by a 99mTc-PYP planar scintigraphy. Patients in whom presence of ≥ 2 uptake was confirmed by SPECT imaging were included. Their clinical, laboratory and echocardiographic data were collected.<h4>Results</h4>Out of 75 patients (mean age 65±12 years, LVEF 35.8±7.9%) included in this study, 7 (9.3%) patients (mean age 75±6 years, LVEF 32.0±8.3%) had ATTR-CA. Patients with ATTR-CA were more symptomatic at diagnosis (NYHA FC 3-4 (86% vs 35% (p = 0.03)) and had a more severe clinical course evident by recurrent hospitalizations for HF, and a need for intravenous diuretic treatment (p = 0.04 and p<0.01, respectively) at follow-up, compared with patients with no ATTR-CA. Patients with ATTR-CA had similar LVEF but a clear trend for larger LV mass index (157.1±60.6 g/m2 vs. 121.0±39.5 g/m2, p = 0.07) and a larger proportions of ATTR-CA patients had IVS thickness >13 mm (57.1% vs 13.1%, p = 0.02) as compared to HF patients with no ATTR-CA.<h4>Conclusion</h4>In our study, a meaningful percentage of patients with unexplained LV dysfunction had a co-existing ATTR-CA indicating that the clinical heterogeneity of ATTR-CA is much broader than previously thought. |
| format | Article |
| id | doaj-art-70ec845e9cab478ea1c7e82ef99c724a |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-70ec845e9cab478ea1c7e82ef99c724a2025-08-20T02:54:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01167e025410410.1371/journal.pone.0254104Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction.Sorel GolandIgor VolodarskyYacov FabricantShay LivschitzSagi TshoriValeri CuciucLiaz ZilbermanIrena FugenfirovValeri MeledinSara ShimoniSagie JosfbergJacob George<h4>Aim</h4>Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) with preserved left ventricular ejection fraction (LVEF), typically presenting as restrictive cardiomyopathy. The potential co-existence of ATTR-CA with systolic heart failure has not been studied. The aim of this study is to describe the prevalence of ATTR-CA and its clinical characteristics in HF patients with reduced LVEF.<h4>Methods</h4>Patients with an unexplained cause of LV systolic dysfunction were screened for ATTR-CA by a 99mTc-PYP planar scintigraphy. Patients in whom presence of ≥ 2 uptake was confirmed by SPECT imaging were included. Their clinical, laboratory and echocardiographic data were collected.<h4>Results</h4>Out of 75 patients (mean age 65±12 years, LVEF 35.8±7.9%) included in this study, 7 (9.3%) patients (mean age 75±6 years, LVEF 32.0±8.3%) had ATTR-CA. Patients with ATTR-CA were more symptomatic at diagnosis (NYHA FC 3-4 (86% vs 35% (p = 0.03)) and had a more severe clinical course evident by recurrent hospitalizations for HF, and a need for intravenous diuretic treatment (p = 0.04 and p<0.01, respectively) at follow-up, compared with patients with no ATTR-CA. Patients with ATTR-CA had similar LVEF but a clear trend for larger LV mass index (157.1±60.6 g/m2 vs. 121.0±39.5 g/m2, p = 0.07) and a larger proportions of ATTR-CA patients had IVS thickness >13 mm (57.1% vs 13.1%, p = 0.02) as compared to HF patients with no ATTR-CA.<h4>Conclusion</h4>In our study, a meaningful percentage of patients with unexplained LV dysfunction had a co-existing ATTR-CA indicating that the clinical heterogeneity of ATTR-CA is much broader than previously thought.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0254104&type=printable |
| spellingShingle | Sorel Goland Igor Volodarsky Yacov Fabricant Shay Livschitz Sagi Tshori Valeri Cuciuc Liaz Zilberman Irena Fugenfirov Valeri Meledin Sara Shimoni Sagie Josfberg Jacob George Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. PLoS ONE |
| title | Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. |
| title_full | Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. |
| title_fullStr | Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. |
| title_full_unstemmed | Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. |
| title_short | Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. |
| title_sort | wild type ttr amyloidosis among patients with unexplained heart failure and systolic lv dysfunction |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0254104&type=printable |
| work_keys_str_mv | AT sorelgoland wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT igorvolodarsky wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT yacovfabricant wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT shaylivschitz wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT sagitshori wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT valericuciuc wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT liazzilberman wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT irenafugenfirov wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT valerimeledin wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT sarashimoni wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT sagiejosfberg wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction AT jacobgeorge wildtypettramyloidosisamongpatientswithunexplainedheartfailureandsystoliclvdysfunction |